Basic Information
Procysbi
Regulatory Information
EMEA/H/C/002465
September 5, 2013
June 27, 2013
16
September 22, 2023
Company Information
Italy
Via Palermo 26/A 43122 Parma
CHIESI FARMACEUTICI S.P.A.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Procysbi. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Procysbi. For practical information about using Procysbi, patients should read the package leaflet or contact their doctor or pharmacist.